ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Renal Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1652789
This article is part of the Research TopicReviews in Renal Pharmacology: 2024View all 22 articles
Clinical efficacy and safety of Tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: A Systematic Review and Meta-Analysis
Provisionally accepted
- The First School of Clinical Medicine，Zhejiang Chinese Medical University, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Idiopathic membranous nephropathy (IMN) is a common cause of nephrotic syndrome in adults, with current immunosuppressive therapies often limited by incomplete efficacy, significant toxicity, and high cost. Extracts from Tripterygium wilfordii, particularly its glycosides (TWG), have emerged as a potential alternative with immunomodulatory properties. Objectives: To evaluate the clinical efficacy and safety of TWG in the treatment of IMN. Methods: We systematically searched PubMed, Embase, Cochrane Library, and Chinese databases from inception to September 2025. Randomized controlled trials (RCTs) and observational studies comparing TWG with standard therapies were included. Risk ratios (RR) and standardized mean differences (SMD) were pooled using a random-effects model. Results: This meta-analysis incorporated 20 studies (1,789 patients). TWG significantly improved the total response rate (RR = 1.27; 95% confidence interval(CI): 1.12–1.44), complete remission rate (RR = 1.81; 95% CI: 1.13–2.90), and reduced 24-hour urinary protein (SMD= -2.09; 95% CI: -3.46 to -0.71) and recurrence risk (RR = 0.56; 95% CI: 0.37–0.86). However, the evidence was characterized by high heterogeneity (I² > 50% for most efficacy outcomes) and a high risk of bias in 17 of the 20 included studies. No significant difference was observed in serum albumin (SMD = 1.20; 95% CI: -0.25 to 2.64) or the overall incidence of inadequately reported adverse events (RR = 0.93; 95% CI: 0.65–1.34). Conclusions: TWG may represent a beneficial therapeutic strategy for IMN, potentially improving remission rates and reducing proteinuria. However, the conclusiveness of these findings is constrained by the high risk of bias in the primary studies, substantial heterogeneity, and inadequate safety reporting. Future robust, multi-regional RCTs are required to definitively establish its efficacy and safety profile.
Keywords: Tripterygium wilfordii glycosides, Idiopathic membranous nephropathy, Meta-analysis, Systematic review, clinical efficacy, Safety
Received: 24 Jun 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Liu and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ying Liu, 202011110611003@zcmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.